此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Apatinib for the Elderly Advanced Gastric Cancer

2022年3月14日 更新者:Jiuda Zhao、Affiliated Hospital of Qinghai University

A Multicenter, Single-arm, Phase Ⅱ Clinical Trial of Apatinib Monotherapy in Elderly Patients With Advanced Gastric Cancer(GC)

The purpose of our study is to assess the efficacy and safety of apatinib in elderly advanced gastric cancer patients, and to find the relationship between the expression of VEGFR-2 and efficacy of apatinib treatment.

研究概览

地位

完全的

条件

干预/治疗

详细说明

The trial is funded by Chinese Society of Clinical Oncology-Beijing Xisike Clinical Oncology Research Fundation. The trial is prepared to be registered on the clinicaltrail.gov.

Quality assurance plan: Every participant is enrolled or excluded by two practiced investigators. And two investigators participate in all steps of the trail, including the record of the data, which is compared by the investigators. If the data is consistent, the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the staff of research and financial department of Affliated Hospital of Qinghai University.

Data check: The investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.

Source data verification: The investigators assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms.

Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information, and normal ranges if relevant.

Standard Operating Procedures to address registry operations and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators.

Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 47 participants to take part in the trail. The investigators can recruit about 20 participants every year according to previous experiences, so the investigators should recruit about two years.

Plan for missing data: The investigators would collect as much data as possible, and the investigators exclude the participants who cannot cooperate on recruitment. And the investigators manage situations according to statistical principles where variables are reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results.

Statistical analysis plan: Statistical analyses would be performed by using SPSS software, version 13.0 (SPSS Inc., IL, USA). Survival analysis would be performed using Kaplan-Meier methodology. Fisher's exact test would be used to analyze the efficacy of treatment. Cox proportional hazards model would be used for multivariate analysis. The level of significance is defined as P < 0.05.

研究类型

介入性

注册 (实际的)

48

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Qinghai
      • Xining、Qinghai、中国、810000
        • Affiliated Hospital of Qinghai University
      • Xining、Qinghai、中国、810000
        • People's Hospital of Qinghai Province
      • Xining、Qinghai、中国、810000
        • Qinghai Red Cross Hospital
      • Xining、Qinghai、中国、810000
        • The Fifth People's Hospital of Qinghai Province
    • Shanxi
      • Yangquan、Shanxi、中国、045000
        • Yangquan No.1 People's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

60年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Elderly patients (aged ≥ 60 years) with histologically confirmed advanced adenocarcinoma of the stomach or gastroesophageal junction;
  2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
  3. Progression with or intolerance to one or more lines of chemotherapy;
  4. At least one measurable lesion as defined by RECIST 1.1;
  5. With acceptable hematologic, cardiac, hepatic, pulmonary and renal function;
  6. Can take apatinib orally;
  7. Estimated life expectancy ≥ 3 months.

Exclusion Criteria:

  1. Patients cannot take apatinib orally for any reason;
  2. Patients with uncontrolled central nervous system (CNS) metastases;
  3. Patients with massive hydrothorax or ascites;
  4. Proteinuria 2+ or 24-hour urinary protein ≥ 1g;
  5. Newly-happened traumatism or pathological fracture;
  6. Estimated life expectancy ˂ 3 months;
  7. Received chemotherapy in the past 28 days before enrollment;
  8. Patients with uncontrolled blood pressure on medication (≥ 140/90 mmHg);
  9. Patients with bleeding tendency, receiving thrombolytics or anticoagulants, receiving intravenous antibiotic treatment, had received bevacizumab or other VEGF TKIs before, or with other primary malignancy (except basal cell skin cancer or cervical carcinoma in situ).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Apatinib Group
take apatinib orally (500mg/d or 250mg/d, once a day, continuously )
take apatinib orally until disease progression or appearance of unbearable toxicity
其他名称:
  • Apatinib group

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-free survival (PFS)
大体时间:1 year
PFS was defined to be the time from registration to the date of disease progress sion or death resulting from any cause.
1 year

次要结果测量

结果测量
措施说明
大体时间
Objective response rate (ORR)
大体时间:1 year
ORR was defined as the proportion of eligible patients who achieved a confirmed complete response(CR )or partial response (PR) by RECIST 1.1 criteria evaluated by the investigators.
1 year
Disease control rate (DCR)
大体时间:1 year
DCR was defined as the proportion of patients who achieved CR, PR and stable disease (SD) for at least 8 weeks.
1 year
Overall survival (OS)
大体时间:1 year
OS was defined to be the time from registration to the date of death resulting from any cause or the last follow-up visit.
1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2017年6月5日

初级完成 (实际的)

2019年12月1日

研究完成 (实际的)

2020年6月2日

研究注册日期

首次提交

2017年4月1日

首先提交符合 QC 标准的

2017年4月1日

首次发布 (实际的)

2017年4月7日

研究记录更新

最后更新发布 (实际的)

2022年3月15日

上次提交的符合 QC 标准的更新

2022年3月14日

最后验证

2022年3月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Apatinib的临床试验

订阅